These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38074736)

  • 1. Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model.
    Choi W; Shim E
    Front Public Health; 2023; 11():1280412. PubMed ID: 38074736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
    Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.
    Nagano M; Kamei K; Matsuda H; Takahashi C; Yang J; Wada K; Yonemoto N
    Expert Rev Vaccines; 2024; 23(1):349-361. PubMed ID: 38411109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of vaccination against COVID-19 in China.
    Zhou H; Ding N; Han X; Zhang H; Liu Z; Jia X; Yu J; Zhang W
    Front Public Health; 2023; 11():1037556. PubMed ID: 36960359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.
    Le P; Rothberg MB
    J Gen Intern Med; 2017 Feb; 32(2):159-167. PubMed ID: 27743284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
    Li R; Liu H; Fairley CK; Zou Z; Xie L; Li X; Shen M; Li Y; Zhang L
    Int J Infect Dis; 2022 Jun; 119():87-94. PubMed ID: 35338008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
    Kohli MA; Maschio M; Joshi K; Lee A; Fust K; Beck E; Van de Velde N; Weinstein MC
    J Med Econ; 2023; 26(1):1532-1545. PubMed ID: 37961887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
    Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
    BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
    Wang Y; Luangasanatip N; Pan-Ngum W; Isaranuwatchai W; Prawjaeng J; Saralamba S; Painter C; Briones JR; Teerawattananon Y
    Eur J Health Econ; 2023 Jul; 24(5):735-748. PubMed ID: 35951243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.
    Orangi S; Ojal J; Brand SP; Orlendo C; Kairu A; Aziza R; Ogero M; Agweyu A; Warimwe GM; Uyoga S; Otieno E; Ochola-Oyier LI; Agoti CN; Kasera K; Amoth P; Mwangangi M; Aman R; Ng'ang'a W; Adetifa IM; Scott JAG; Bejon P; Keeling MJ; Flasche S; Nokes DJ; Barasa E
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35914832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Kim DeLuca E; Gebremariam A; Rose A; Biggerstaff M; Meltzer MI; Prosser LA
    Vaccine; 2023 Jun; 41(29):4239-4248. PubMed ID: 37291022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea.
    Shim E
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Tanaka M; Okubo R; Hoshi SL; Ishikawa N; Kondo M
    Vaccine; 2022 Feb; 40(7):1010-1018. PubMed ID: 35039195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.
    Yun JW; Choi MJ; Shin GS; Lim JO; Noh JY; Kim YK; Song JY; Kim WJ; Choi SE; Cheong HJ
    PLoS One; 2019; 14(1):e0209643. PubMed ID: 30682030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.